ncRNA basic information ncRNA ID: MIMAT0005591 ncRNA Database: miRBase ncRNA Name: miR-1236-3p ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: PR-qPCR ncRNA Target Gene: TPT1 ncRNA Pathway: pim-3 signaling pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: In this study, we found that the expression level of miR-1236-3p was significantly decreased in lung cancer tissues and A549 cell line. In addition, the half maximal inhibitory concentration (IC50) of DDP in A549 cells was significantly lower than that in A549/DDP cells, while the expression level of miR-1236-3p was prominently down-regulated in A549/DDP cells. Combining the online tool TargetScan and a dual-luciferase reporter assay, tumor protein, translationally-controlled 1 (TPT1) was proved to be the direct target gene of miR-1236-3p. The MTT and flow cytometry assays demonstrated that up-regulation of miR-1236-3p could markedly inhibit A549/DDP cell proliferation but promote apoptosis, which could be significantly reversed by pcDNA3.1-TPT1 plasmids. Finally, we further demonstrated that miR-1235-3p could restrain the expression levels of TPT1, Pim-3, phosphate-Bcl-2-associated death promoter (p-BAD) and B-cell lymphoma-extra large (Bcl-XL) in A549/DDP cells, while the inhibition could be reversed by pcDNA3.1-TPT1 as well. In a word, our study demonstrated that miR-1236-3p could reverse DDP resistance by modulation of TPT1 gene and inhibition of Pim-3 signaling pathway in lung cancer cells. Drug Response: resistant

Cancer basic information Cancer: lung cancer Tissue/Cell: cell line (BESA-2B,A549)

Other information Title: microRNA-1236-3p Regulates DDP Resistance in Lung Cancer Cells. Journal: Open Med (Wars) Published: 2019 PubMed ID: 30805558